Search Keyword:


Search option:


IID90042
UniprotP04326
ProteinProtein Tat
Genetat
OrganismHuman immunodeficiency virus type 1 group M subtype B (isolate PCV12)
Sequence LLPS PhaSepDB
PhaSePro
LLPSDB
DrLLPS
Network xml rdf
Structure
Experiment
  :order   disorder   conflict   PDB cluster   ProS   Pfam Domain   SEG
86
 order/disorder by at least rule
     disorder by at least rule
     order by at least rule
 order/disorder by majority rule
Seq 48-60 Hetero dimer : IID50009Complex
 Evidence X-RAY 5svz B Reference
       Region 5svz B 48-55 order
       Region 5svz B 56-60 disorder
SeqProS possible 48-55 Same region of the Tat homolog (P04608, 95.3% identity) is disordered in the free state. Hetero dimer : IID50009Complex
       Region 5svz B 48-55 order
Seqacetylation
    28-28 N6-acetyllysine; by host PCAF
    50-50 N6-acetyllysine; by host EP300 and GCN5L2
    51-51 N6-acetyllysine; by host EP300 and GCN5L2
 
Prediction
NeProc
Disorder 1-6,49-86
Order 7-48
ProS 1-6,57-71,77-86
Pfam Hmmer
PF00539 2-68 2.2e-40
SEG 49-57
Function
Function in SwissProt
Extracellular circulating Tat can be endocytosed by surrounding uninfected cells via the binding to several surface receptors such as CD26, CXCR4, heparan sulfate proteoglycans (HSPG) or LDLR. Neurons are rarely infected, but they internalize Tat via their LDLR. Through its interaction with nuclear HATs, Tat is potentially able to control the acetylation-dependent cellular gene expression. Modulates the expression of many cellular genes involved in cell survival, proliferation or in coding for cytokines or cytokine receptors. Tat plays a role in T-cell and neurons apoptosis. Tat induced neurotoxicity and apoptosis probably contribute to neuroAIDS. Circulating Tat also acts as a chemokine-like and/or growth factor-like molecule that binds to specific receptors on the surface of the cells, affecting many cellular pathways. In the vascular system, Tat binds to ITGAV/ITGB3 and ITGA5/ITGB1 integrins dimers at the surface of endothelial cells and competes with bFGF for heparin-binding sites, leading to an excess of soluble bFGF.